Navigation Links
Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
Date:9/7/2012

nding.  We may determine such a dose based on an efficacy signal or an acceptable safety profile in the Phase 1b trial and/or upon calculating it from ongoing PET imaging trials in cancer patients with LIGHT (since PET imaging is quantitative, enabling determination of tumor radiation exposure at a given dose level).  Preclinical experiments in vitro (in cell culture) and in more than a dozen in vivo (in animals) models have demonstrated selective killing of cancer cells along with a benign safety profile.  In view of HOT's selective uptake and retention in a wide range of solid tumors and in cancer stem cells, its single-agent efficacy in animal models and its non-specific mechanism of cancer-killing (radiation), we are first developing HOT as a monotherapy for solid tumors with significant unmet medical need.

About Novelos Therapeutics, Inc.
We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer.  Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells.  Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells.  This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.  I-124-CLR1404 (LIGHT) is a small-molecule cancer-targeted PET imaging agent.  We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing across 11 solid tumor indications.  I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells.  We believe HOT also has first-in-class potential.  HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to en
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
7. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
8. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... CITY, Calif. , May 1, 2015  AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that Timothy E. Morris , chief financial ...  Details of the events are as follows: ... May 5 Location:  The Omni Berkshire Place, ...
(Date:5/1/2015)... YORK , May 1, 2015  Shares of ... 70% of their value yesterday following the results of ... glaucoma therapy, Rhopressa.  Despite the trial failing to meet ... that positive results may come from future studies. ... brief company overview, current pipeline, financial review, analyst summary, ...
(Date:4/30/2015)... April 30, 2015 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the fourth ... Fourth quarter and fiscal 2015 overview: , ... fourth quarter, up 33% over last year,s comparable quarter, ... , Diluted EPS of $0.50 for the fourth ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24
... 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or ... leading pharmaceutical company specializing in the development, manufacturing, ... China, today announced that Shanghai Celgen Bio-Pharmaceutical Co., ... a 35% equity interest, has received new drug ...
... With tight budgets continuing to constrain its healthcare markets, ... modest profit in the third quarter of fiscal year 2011 ... income for the quarter ending March 31, was about $60,000, ... $37,000, or zero cents per share, for the previous year,s ...
Cached Medicine Technology:Simcere Announces Recent Progress of Qiangke's Registration 2Allied Healthcare Earns Modest Profit in Tight Market 2Allied Healthcare Earns Modest Profit in Tight Market 3Allied Healthcare Earns Modest Profit in Tight Market 4
(Date:5/3/2015)... 2015 HealthPostures, a pioneering ergonomics ... its appearance at the , May 5 - 7, ... will exhibit at the conference include its bestselling TaskMate ... solutions is the 6100 TaskMate Executive. Features of the ... adjustable keyboard tray, extended platform work surface and supply ...
(Date:5/2/2015)... May 02, 2015 ProText Kinetic 2 is ... in Final Cut Pro X. ProText Kinetic 2 features ... Final Cut Pro X . Easily create interactive ... Pixel Film Studios' ProText Kinetic 2. , Using ProText Kinetic ... staggering two ProText Kinetic presets in the FCPX timeline. ...
(Date:5/2/2015)... May 02, 2015 Kare Visits LLC. launched ... for busy caregivers. Kare Visits offers relief for caregivers ... living facilities. According to the Caregiver Action Network, ... average of 20 hours a week caring for an elderly ... cost to hire a nurse, a caregiver is now empowered ...
(Date:5/1/2015)... May 02, 2015 The Venetian on ... http://www.thevenetiangracebay.com , and it is elegant and sophisticated, ... white and attractive turquoise hues of Grace Bay Beach. ... seven percent of leisure travelers used their smartphones throughout ... were used in the planning and researching and continued ...
(Date:5/1/2015)... 2015 TROY Healthcare Solutions is proud ... User Group (RUG) Conference in Atlanta, GA from May ... Group Conference provides a forum for client-to-client presentations, continuing ... aspects of electronic medical record operations, as well as ... , In addition to sponsoring the event, TROY Healthcare ...
Breaking Medicine News(10 mins):Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3
... HealthDay Reporter , TUESDAY, Nov. 8 (HealthDay News) -- Doctors ... perform the tests, even when guidelines don,t recommend it. The ... but did interpret the results in his or her own office, ... Journal of the American Medical Association . The ...
... School of Medicine (BUSM) and Boston Medical Center (BMC), report ... number of cases of child maltreatment. The study, which is ... Pediatrics , is the first to examine the validity of ... of an injury and their decision to report a suspicious ...
... derived from a Chinese herb, has been the ... the malaria parasite becoming resistant, the World Health ... anti-malarial drug. But there are different formulations and ... Scientists from the Institute of Tropical Medicine (ITM) ...
... November 8, 2011: Clinical researchers here reported the first results ... as an adjunct to catheter-based procedures in patients with severely ... The results showed a 60% reduction in major bleeding ... treated with Angiomax compared to patients treated with heparin. This ...
... West Orange, NJ. Nov. 8, 2011. Two neuropsychologists at ... in grants by the National Multiple Sclerosis Society. Nancy ... "Speed of Processing Training for Improving Processing Speed in ... individuals with multiple sclerosis (MS) have significant impairments in ...
... , PHILADELPHIA Thomas Jefferson University Hospital is ... to offer the recently-approved U.S. Food and Drug Administration ... BRAF mutation (which occurs in about half of all ... new, potentially life-saving drug. In August, the ...
Cached Medicine News:Health News:Heart Stress Test Likelier When Doctor Owns Equipment: Study 2Health News:Heart Stress Test Likelier When Doctor Owns Equipment: Study 3Health News:Study finds primary health care providers fail to report substantial cases of child abuse 2Health News:New artemisinin-based treatment against malaria promising 2Health News:First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions 2Health News:Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients 2
...
...
...
... employs titanium alloy plasma spray porous ... surface. Biomet's ArCom processed polyethylene is ... bearing material. The Maxim Knee System's ... tibial components offer excellent sizing options ...
Medicine Products: